Advances in pancreatic cancer treatment

Hossein Taghizadeh

doi:10.1007/s12254-024-01020-5

Advances in pancreatic cancer treatment

Hossein Taghizadeh

Klinische Abteilung für Innere Medizin I (UK St. Pölten)

Publikation: Beitrag in Fachzeitschrift (peer-reviewed) › Übersichtsartikel

1 Zitat (Scopus)

Abstract

Pancreatic cancer, one of the most challenging malignancies to treat, is characterized by poor survival rates. The identification of novel effective therapies, optimization of treatments for the elderly population, and elucidation of the role of chemoradiotherapy are critical issues. Recent studies presented at the American Society of Clinical Oncology (ASCO) 2024 annual meeting have demonstrated advancements in the treatment of this aggressive disease. This review summarizes three notable studies: the phase I trial of IBI389, the phase II GIANT trial, and the phase II/III GABARNANCE trial, each contributing new insights into therapeutic strategies for pancreatic ductal adenocarcinoma (PDAC).

Originalsprache	Englisch
Seiten (von - bis)	22-25
Seitenumfang	4
Fachzeitschrift	Memo - Magazine of European Medical Oncology
Jahrgang	18
Ausgabenummer	1
DOIs	https://doi.org/10.1007/s12254-024-01020-5
Publikationsstatus	Veröffentlicht - Feb. 2025

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gute Gesundheit und Wohlergehen

ASJC Scopus Sachgebiete

Hämatologie
Onkologie

Zugriff auf Dokument

10.1007/s12254-024-01020-5

https://link.springer.com/10.1007/s12254-024-01020-5

Andere Dateien und Links

Verknüpfung zur Publikation in Scopus

Dieses zitieren

@article{9e4270c5e8bb41f487422124e74bb8f0,

title = "Advances in pancreatic cancer treatment",

abstract = "Pancreatic cancer, one of the most challenging malignancies to treat, is characterized by poor survival rates. The identification of novel effective therapies, optimization of treatments for the elderly population, and elucidation of the role of chemoradiotherapy are critical issues. Recent studies presented at the American Society of Clinical Oncology (ASCO) 2024 annual meeting have demonstrated advancements in the treatment of this aggressive disease. This review summarizes three notable studies: the phase I trial of IBI389, the phase II GIANT trial, and the phase II/III GABARNANCE trial, each contributing new insights into therapeutic strategies for pancreatic ductal adenocarcinoma (PDAC).",

keywords = "Borderline resectable, Claudin 18.2, Pancreatic cancer, PDAC, Targeted therapy",

author = "Hossein Taghizadeh",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2025.",

year = "2025",

month = feb,

doi = "10.1007/s12254-024-01020-5",

language = "English",

volume = "18",

pages = "22--25",

journal = "Memo - Magazine of European Medical Oncology",

issn = "1865-5041",

publisher = "Springer",

number = "1",

}

TY - JOUR

T1 - Advances in pancreatic cancer treatment

AU - Taghizadeh, Hossein

N1 - Publisher Copyright: © The Author(s) 2025.

PY - 2025/2

Y1 - 2025/2

N2 - Pancreatic cancer, one of the most challenging malignancies to treat, is characterized by poor survival rates. The identification of novel effective therapies, optimization of treatments for the elderly population, and elucidation of the role of chemoradiotherapy are critical issues. Recent studies presented at the American Society of Clinical Oncology (ASCO) 2024 annual meeting have demonstrated advancements in the treatment of this aggressive disease. This review summarizes three notable studies: the phase I trial of IBI389, the phase II GIANT trial, and the phase II/III GABARNANCE trial, each contributing new insights into therapeutic strategies for pancreatic ductal adenocarcinoma (PDAC).

AB - Pancreatic cancer, one of the most challenging malignancies to treat, is characterized by poor survival rates. The identification of novel effective therapies, optimization of treatments for the elderly population, and elucidation of the role of chemoradiotherapy are critical issues. Recent studies presented at the American Society of Clinical Oncology (ASCO) 2024 annual meeting have demonstrated advancements in the treatment of this aggressive disease. This review summarizes three notable studies: the phase I trial of IBI389, the phase II GIANT trial, and the phase II/III GABARNANCE trial, each contributing new insights into therapeutic strategies for pancreatic ductal adenocarcinoma (PDAC).

KW - Borderline resectable

KW - Claudin 18.2

KW - Pancreatic cancer

KW - PDAC

KW - Targeted therapy

UR - https://www.scopus.com/pages/publications/85217243410

U2 - 10.1007/s12254-024-01020-5

DO - 10.1007/s12254-024-01020-5

M3 - Review article

SN - 1865-5041

VL - 18

SP - 22

EP - 25

JO - Memo - Magazine of European Medical Oncology

JF - Memo - Magazine of European Medical Oncology

IS - 1

ER -

Advances in pancreatic cancer treatment

Abstract

UN SDGs

ASJC Scopus Sachgebiete

Zugriff auf Dokument

Andere Dateien und Links

Fingerprint

Dieses zitieren